Literature DB >> 12582190

Renal artery stent placement: complications at a single tertiary care center.

Vladimir Ivanovic1, Michael A McKusick, C Michael Johnson, Enrique A Sabater, James C Andrews, Jerome F Breen, Haraldur Bjarnason, Sanjay Misra, Anthony W Stanson.   

Abstract

PURPOSE: To describe complications after renal artery stent placement in patients with atherosclerotic renal artery stenosis (RAS) at a single tertiary care center and analyze the risk factors for these complications.
MATERIALS AND METHODS: Medical records and angiograms of 171 patients who underwent a total of 179 consecutive percutaneous transluminal renal artery stent placement (PTRS) procedures for atherosclerotic RAS were retrospectively reviewed. Data on patient comorbidities, procedure indication, lesion location, serum creatinine level, and procedure-related complications were analyzed. The Wilcoxon rank-sum test was used to assess the association of continuous risk factors with complications, and the chi(2) test was used to assess the association of categoric risk factors with outcomes.
RESULTS: The technical success rate for PTRS was 98%. Major complications included renal infarction in five patients (2.8%), permanently increased serum creatinine level in 10 patients (5.6%) that required hemodialysis in five (2.8%), blood transfusion in four patients (2.2%), surgical intervention for procedure-related complications in two patients (1.1%), and deep vein thrombosis in one patient (0.6%). Overall, major complications occurred in 15 procedures (8.4%). Death within 30 days after PTRS occurred in two patients (1.1%), but neither death was definitively caused by the procedure. No risk factors were found to be significantly (P <.05) associated with major complications. Patients with renal artery site or renal function complications tended to be older (P =.01) and have higher creatinine levels (P =.06).
CONCLUSIONS: Renal artery stent placement allows treatment of advanced atheromatous RAS in patients with significant medical and surgical comorbidities. Complications are frequent but few have long-term significance.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12582190     DOI: 10.1097/01.rvi.0000058324.82956.2a

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  7 in total

1.  Experience of stenting for atherosclerotic renal artery stenosis in a cardiac catheterization laboratory: technical considerations and complications.

Authors:  Percy P Jokhi; Krishnan Ramanathan; Simon Walsh; Anthony Y Fung; Jacqueline Saw; Rebecca S Fox; Nadia Zalunardo; Christopher E Buller
Journal:  Can J Cardiol       Date:  2009-08       Impact factor: 5.223

Review 2.  Renovascular hypertension update.

Authors:  Stephen C Textor
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

Review 3.  Renovascular hypertension in 2007: where are we now?

Authors:  Stephen C Textor
Journal:  Curr Cardiol Rep       Date:  2007-11       Impact factor: 2.931

4.  Mortality and Renal Replacement Therapy after Renal Artery Stent Placement for Atherosclerotic Renovascular Disease.

Authors:  Sanjay Misra; Ankaj Khosla; Jake Allred; William S Harmsen; Stephen C Textor; Michael A McKusick
Journal:  J Vasc Interv Radiol       Date:  2016-06-11       Impact factor: 3.464

5.  Renal subcapsular hematoma : a consequence of reperfusion injury of long standing renal artery stenosis.

Authors:  Kyung Pyo Kang; Sik Lee; Won Kim; Young-Min Han; Sung Kyew Kang; Sung Kwang Park
Journal:  Electrolyte Blood Press       Date:  2007-12-31

6.  Acute renal infarction presenting with acute abdominal pain secondary to newly discovered atrial fibrillation: a case report and literature review.

Authors:  Sherif Ali Eltawansy; Shil Patel; Mana Rao; Samaa Hassanien; Mihir Maniar
Journal:  Case Rep Emerg Med       Date:  2014-12-29

Review 7.  Percutaneous revascularization for ischemic nephropathy: the past, present, and future.

Authors:  Stephen C Textor; Sanjay Misra; Gustavo S Oderich
Journal:  Kidney Int       Date:  2012-11-14       Impact factor: 10.612

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.